Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)'. The following are the other relevant details related to the trial:
Therapeutic Area: Cardiology
Trial Centre(s):
Changi General Hospital
National Heart Centre
National University Hospital
Ng Teng Fong General Hospital
Sengkang General Hospital
Tan Tock Seng Hospital
Trial Status: Ongoing, Recruiting
Principal Investigator(s):
Dr Chai Siang Chew
Dr Tan Ru San
Dr Yeo Tee Joo
Dr Andie Hartanto Djohan
Dr...